他汀类药物对骨髓增殖性肿瘤患者心血管及血液学结局的影响
这项多中心回顾性队列研究纳入669例至少接受过一次经胸超声心动图的骨髓增殖性肿瘤(MPN)患者,采用IPTW竞争风险回归分析。结果显示,他汀使用与主要不良心血管事件(MACE)风险降低相关,尤其在ET或PV患者中,但与全因死亡或MPN疾病进展无关。该人群中他汀治疗存在使用不足。
要点
- 在MPN患者中,他汀使用与MACE风险降低相关,尤其在ET或PV患者中。
- 他汀使用与全因死亡或MPN疾病进展无显著关联。
- 该MPN人群中他汀治疗存在使用不足,需进一步研究获益人群。
核心结论
- 在接受经胸超声心动图的MPN患者中,他汀使用与MACE风险降低相关,尤其在ET或PV患者中。
- 他汀使用与全因死亡或MPN疾病进展无显著关联。
研究设计与样本
- 多中心回顾性队列研究,纳入2010至2024年间至少接受1次经胸超声心动图(TTE)的MPN患者共669例。
- 采用逆概率处理加权(IPTW)竞争风险回归分析,评估指数TTE时他汀使用与MACE、MPN疾病进展及全因死亡的关联。
主要发现
- 共669例患者,43.9%使用他汀,50.5%为女性,83.9%为白人,78.8%有JAK2驱动突变,72.9%有I类指南他汀治疗指征。
- PV患者267例(39.9%),ET患者234例(35.0%),MF患者168例(25.1%)。
- IPTW后,他汀使用与MACE风险降低相关,但与MPN疾病进展或全因死亡无关。
- 在ET或PV患者中,他汀使用与MACE风险降低相关,但与MPN进展或全因死亡无关。
- 在MF患者中,他汀使用与MACE、白血病进展或全因死亡均无差异。
临床怎么用
- 对于MPN患者,尤其ET或PV患者,他汀治疗可能降低MACE风险,但需结合指南指征评估使用。
- 该人群中他汀治疗使用不足,应关注有指征患者的他汀启用。
局限性
- 回顾性研究设计可能残留混杂。
- 仅纳入接受过TTE的患者,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), are chronic myeloid neoplasms associated with increased risk of cardiovascular disease (CVD). Statins are a common group of cholesterol-lowering medications recommended for the primary and secondary prevention of CVD, including arterial thrombotic events. Emerging evidence suggests that statins may reduce the risk of developing MPNs and their use may be associated with improved survival. However, the effect of statins on cardiovascular and hematologic outcomes among patients with MPNs remains uncharacterized. We conducted a multicenter retrospective cohort study of patients with MPNs who had at least 1 transthoracic echocardiogram (TTE) from 2010 to 2024. Inverse probability of treatment weighting (IPTW) competing-risk regression analysis was performed to assess the association between statin use at time of index TTE on major adverse cardiovascular events (MACE), MPN disease progression, and all-cause death. Patients with MPN were analyzed as a whole and separately by type (ET or PV and MF). A total of 669 patients were included, 43.9% were on statin use, 50.5% were female, 83.9% were White, 78.8% had JAK2 driver mutation, and 72.9% had class I guideline indication for statin therapy. There were 267 (39.9%) patients with PV, 234 (35.0%) with ET, and 168 (25.1%) with MF. After IPTW, statin use was associated with lower risk of MACE but not MPN disease progression or all-cause death. Among patients with ET or PV, statin use was associated with lower risk of MACE but not MPN progression or all-cause death. Among patients with MF, there was no difference in MACE, leukemia progression, or all-cause death. Among patients with MPNs who underwent TTE, statin use was associated with lower risk of MACE, particularly among patients with ET or PV. However, there was no association between statin use and all-cause death or MPN disease progression. Statin therapy is underused in this patient population. Further studies are needed to explore the utility of statin therapy in patients with MPN and identify patients who would benefit most from statin therapy.
引用
- Leiva O, Soo S, Liu OC, et al. Impact of statin use on cardiovascular and hematologic outcomes among patients with myeloproliferative neoplasms. Blood Adv. 2026. PMID: 41499780. doi:10.1182/bloodadvances.2025018724
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。